Skip to content

Five Prime Therapeutics, Inc.

CIK 0001175505

← back to feed
Revenue (TTM)
$17.44M
+543.5% YoY FY Mar 2021
Net Income (TTM)
−$99.55M
+21.1% YoY FY Mar 2021
EPS Diluted (TTM)
−$5.38
−120.5% YoY FY Mar 2021
Gross Margin
—
FY Mar 2021
Operating Margin
-619.8%
FY Mar 2021
Net Margin
-570.9%
FY Mar 2021
Free Cash Flow (TTM)
−$67.64M
FY Mar 2021
Cash
$69.42M
FY Mar 2021
Total Debt
—
FY Mar 2021
Shares Outstanding
46.57M sh
FY Mar 2021

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings